Methyl 3-(6-oxo-1,6-dihydropyridazin-3-yl)benzoate | 1087379-61-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: Methyl 3-(6-oxo-1,6-dihydropyridazin-3-yl)benzoate
• 英文别名: methyl 3-(6-oxo-1H-pyridazin-3-yl)benzoate
• CAS: 1087379-61-0
• 化学式: C₁₂H₁₀N₂O₃
• 分子量: 230.223
• InChiKey: NWJSNVHNSKJCRO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  67.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Methyl 3-(6-oxo-1,6-dihydropyridazin-3-yl)benzoate 在 tris-(dibenzylideneacetone)dipalladium(0) 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  Pyridazinone derivatives displaying highly potent and selective inhibitory activities against c-Met tyrosine kinase

  摘要：

  Over activation of c-Met tyrosine kinase is known to promote tumorigenesis and metastasis, as well as to cause therapeutic resistance. Herein we describe the design, synthesis and biological activities of novel, ATP-competitive, c-Met tyrosine kinase inhibitors that are members of the 6-aryl-2-(3-(heteroarylamino) benzyl)pyridazinone family. A structure-activity relationship (SAR) study of these substances led to identification of pyridazinone 19 as a highly selective and potent c-Met tyrosine inhibitor, which displays favorable pharmacokinetic properties in mice and significant antitumor activity against a c-Met driven EBC-1 tumor xenograft. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.11.042
• 作为产物：
  描述：

  甲醇 、 3-(6-氧代-1,6-二氢哒嗪-3-基)苯甲酸 在 氯化亚砜 作用下， 以 甲醇 为溶剂， 反应 24.0h， 生成 Methyl 3-(6-oxo-1,6-dihydropyridazin-3-yl)benzoate
  参考文献：
  名称：

  PYRIDAZINONE DERIVATIVES

  摘要：

  式（I）的化合物，其中R1、R2和R3具有权利要求1中指示的含义，是酪氨酸激酶的抑制剂，特别是Met激酶，并可用于治疗肿瘤。

  公开号：

  US20100179148A1

文献信息

• Pyridazinone derivatives
  申请人：Stieber Frank

  公开号：US08367668B2

  公开（公告）日：2013-02-05

  Compounds of the formula (I), in which R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours.

  公式（I）的化合物，其中R1、R2和R3具有权利要求1中所示的含义，是酪氨酸激酶抑制剂，特别是Met激酶抑制剂，可用于治疗肿瘤等疾病。
• US8367668B2
  申请人：——

  公开号：US8367668B2

  公开（公告）日：2013-02-05
• Pyridazinone derivatives displaying highly potent and selective inhibitory activities against c-Met tyrosine kinase
  作者：Yang Liu、Shiyu Jin、Xia Peng、Dong Lu、Limin Zeng、Yiming Sun、Jing Ai、Meiyu Geng、Youhong Hu

  DOI：10.1016/j.ejmech.2015.11.042

  日期：2016.1

  Over activation of c-Met tyrosine kinase is known to promote tumorigenesis and metastasis, as well as to cause therapeutic resistance. Herein we describe the design, synthesis and biological activities of novel, ATP-competitive, c-Met tyrosine kinase inhibitors that are members of the 6-aryl-2-(3-(heteroarylamino) benzyl)pyridazinone family. A structure-activity relationship (SAR) study of these substances led to identification of pyridazinone 19 as a highly selective and potent c-Met tyrosine inhibitor, which displays favorable pharmacokinetic properties in mice and significant antitumor activity against a c-Met driven EBC-1 tumor xenograft. (C) 2015 Elsevier Masson SAS. All rights reserved.
• PYRIDAZINONE DERIVATIVES
  申请人：Stieber Frank

  公开号：US20100179148A1

  公开（公告）日：2010-07-15

  Compounds of the formula (I), in which R 1 , R 2 and R 3 have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours.

  式（I）的化合物，其中R1、R2和R3具有权利要求1中指示的含义，是酪氨酸激酶的抑制剂，特别是Met激酶，并可用于治疗肿瘤。